About us
Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies.
Vipergen offers to current and future partners to discover hits/leads for their high value targets, using three proprietary 2nd and 3rd generation DEL technologies.
Vipergen in brief
- Vipergen is a small molecule drug discovery company – with focus on the hit/lead finding process
- Vipergen introduces the YoctoReactor® (yR) and Binder Trap Enrichment® (BTE) – 2nd generation DNA-encoded small-molecule library technologies
- Vipergen introduces the in cell Binder Trap Enrichment® (cBTE) – 3rd generation technology (unique)
- The yR, BTE and cBTE technology platforms are exclusively owned by Vipergen and secured by strong patent positions
- The company is privately owned by Gunnar Kjems and Dr. Nils Hansen
- Board members: Gunnar Kjems (chair) and Dr. Nils Hansen
- Founded by CEO, Dr. Nils Hansen
- Founded in 2005
- Incorporated in Copenhagen, Denmark
- In 2015-23 >85 deals signed, including with top-5 pharma in both USA, EU and Japan
- Strategic partner: Aurigene Pharmaceutical Services for library expansion and integrated end-to-end discovery and development offering
Vipergen team
Allan Beck Christensen
Director, Screening Technologies
Amaya Alzu Farinas
Technician
Andrzej Taranta
Senior Scientist
Caroline Ryberg
Student helper
Charlotte Andersen
Senior Scientist
Frank Sløk
Head of Chemistry
Kristian Klint
Technician
Lars Kolster Petersen
Associate Director, Chemistry
Leif Kongskov Larsen
Director, Biology
Marie Hesse
Research Assistant
Nils Jakob Vest Hansen
CEO
Ole Kristensen
Senior Scientist
Peter Blakskjær
Senior Scientist
Rico Gerup Petersen
Senior Scientist
Rozalia Korbut
Technician
Do you have an inquiry?
Improve the starting point for lead optimization with our cutting-edge technologies. Experience our unique approach to screening that excels, even for challenging targets.